A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-491 in Subjects With Essential Hypertension.

Trial Profile

A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-491 in Subjects With Essential Hypertension.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Apr 2016

At a glance

  • Drugs Azilsartan medoxomil (Primary) ; Olmesartan medoxomil
  • Indications Essential hypertension
  • Focus Registrational; Therapeutic Use
  • Sponsors Takeda Global Research and Development Center
  • Most Recent Events

    • 21 Jun 2010 Results presented at the 20th European Meeting on Hypertension.
    • 03 May 2010 Results were presented at the American Society of Hypertension, Inc. 25th Annual Scientific Meeting, according to a Takeda Global Research and Development Center media release.
    • 03 May 2010 Primary endpoint 'Systolic blood pressure' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top